Stocks · Healthcare · Medical - Diagnostics & Research
Exagen Inc. XGN
$8.17 +3.55% Close, Oct 2, 2026 · NASDAQ · Market cap $197.4M
High risk
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 14.6% in a year.
- The stock is in an uptrend: above its 200-day average for 43 trading days, with the 50-day average above the 200-day.
- Revenue over the last four quarters was $71.1M, up 20.8% from a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 32%
- Revenue growth, 3-year CAGRTop 42%
- Revenue growth accelerationTop 42%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 39%
- Gross marginBottom 45%
- Operating marginBottom 43%
- Accruals (lower is better)Top 10%
- Interest coverBottom 47%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 46%
- Free-cash-flow yieldTop 49%
- EBITDA / enterprise valueBottom 48%
- Sales / enterprise valueTop 36%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 16%
- 6-month returnTop 3%
- 1-year return vs S&P 500Bottom 25%
- Distance from 52-week highBottom 48%
- Trend checklist (0–4)Top 7%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 30%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 9%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 14%
- Maximum drawdown, 3 yearsBottom 37%
- Beta vs S&P 500 (lower is better)Bottom 24%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 20.6% | 20.8% | ↑ |
| Gross margin | 59.4% | 58.6% | ↓ |
| Operating margin | -23.9% | -18.6% | ↑ |
| FCF margin | -27.2% | -10.7% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 20.8% | 20.6% | ↑ | Top 32% |
| Gross margin | 58.6% | 59.4% | ↓ | Bottom 45% |
| Operating margin | -18.6% | -23.9% | ↑ | Bottom 43% |
| Net margin | -26.6% | -28.8% | ↑ | — |
| Free-cash-flow margin | -10.7% | -27.2% | ↑ | — |
| Return on invested capital | -33.0% | — | Bottom 39% | |
| Revenue growth, 3-year CAGR | 13.5% | — | Top 42% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -23.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 4.1%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -40.3 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -2.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.90%
- Shareholder yield
- -1.90%
- Share count change, 1 year
- +14.6%
- Share count change, 3-year CAGR
- +11.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -9.1%
- Average 2-day reaction, last 8
- +11.3%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $8.00
- Target vs current price
- -2.1%
- Analysts with a rating
- 10
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +32.1% | +37.8% | +41.9% | +56.8% | — |
| May 11, 2026 | +29.2% | +34.9% | +23.4% | +42.4% | +125.4% |
| Mar 10, 2026 | +0.0% | -3.8% | -6.5% | -11.2% | +34.3% |
| Nov 4, 2025 | -97.6% | -9.0% | -20.0% | -40.0% | -68.9% |
| Jul 29, 2025 | +0.0% | +14.3% | +19.8% | +33.3% | +58.2% |
| May 5, 2025 | +0.0% | +3.8% | -5.1% | +18.6% | +43.4% |
| Mar 11, 2025 | +25.9% | +18.2% | +27.0% | +43.2% | +158.6% |
| Nov 12, 2024 | +6.7% | -6.1% | +1.0% | +42.4% | +61.6% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.13 | -$0.19 | +32.1% | $19.9M |
| May 11, 2026 | -$0.17 | -$0.24 | +29.2% | $17.3M |
| Mar 10, 2026 | -$0.20 | -$0.20 | +0.0% | $16.6M |
| Nov 4, 2025 | -$0.31 | -$0.16 | -97.6% | $17.2M |
| Jul 29, 2025 | -$0.18 | -$0.18 | +0.0% | $17.2M |
| May 5, 2025 | -$0.20 | -$0.20 | +0.0% | $15.5M |
| Mar 11, 2025 | -$0.20 | -$0.27 | +25.9% | $13.7M |
| Nov 12, 2024 | -$0.28 | -$0.30 | +6.7% | $12.5M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2.79× | — | — | Top 36% |
| Free-cash-flow yield | -3.84% | — | — | Top 49% |
| Earnings yield | -10.04% | — | — | Bottom 46% |
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 44
- Days above the 200-day average
- 43
- 50-day average slope (20 days)
- +23.9%
- 200-day average slope (20 days)
- +1.0%
- Distance from 50-day average
- +15.2%
- Distance from 200-day average
- +69.1%
- RSI (14)
- 56.8
- Relative volume
- 2.29×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 86.2%
- Volatility vs own 5-year history
- 64th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.70
- Correlation with S&P 500
- 0.28
- Current drawdown from 1-year high
- -31.7%
- Maximum drawdown, 3 years
- -77.8%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 17, 2021 | May 1, 2024 | -93.8% | 786 days | Not yet recovered |
| Nov 10, 2020 | Dec 29, 2020 | -28.8% | 33 days | 5 days (Jan 6, 2021) |
| Oct 16, 2020 | Oct 30, 2020 | -10.5% | 10 days | 7 days (Nov 10, 2020) |
| Jan 6, 2021 | Jan 13, 2021 | -10.1% | 5 days | 4 days (Jan 20, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $197.4M
- EPS, diluted (TTM)
- -$0.82
- Revenue (TTM)
- $71.1M
- 52-week range
- $2.59 – $12.23
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $48.3M | $45.6M | $52.5M | $55.6M | $66.6M |
| Gross profit | $27.7M | $21.3M | $29.5M | $33.1M | $38.8M |
| Operating income | -$24.1M | -$46.1M | -$22.8M | -$13.6M | -$14.1M |
| Net income | -$26.9M | -$47.4M | -$23.7M | -$15.1M | -$20.0M |
| EPS (diluted) | -$1.68 | -$2.77 | -$1.34 | -$0.83 | -$0.93 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.5M | $13.7M | $15.5M | $17.2M | $17.2M | $16.6M | $17.3M | $19.9M |
| Net income | -$5.0M | -$3.8M | -$3.8M | -$4.4M | -$7.1M | -$4.7M | -$4.0M | -$3.2M |
| EPS (diluted) | -$0.28 | -$0.20 | -$0.20 | -$0.21 | -$0.31 | -$0.21 | -$0.17 | -$0.13 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$20.3M | -$32.1M | -$14.5M | -$13.3M | -$13.6M |
| Capital expenditure | -$2.4M | -$4.3M | -$828,000 | -$515,000 | -$641,000 |
| Free cash flow | -$22.6M | -$36.5M | -$15.3M | -$13.8M | -$14.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $69.1M | $446,000 | $306,000 | $198,000 | $22.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $24.6M
- Total assets
- $51.9M
- Total liabilities
- $39.7M
- Total debt
- $25.5M
- Net debt
- $959,000
- Shareholders’ equity
- $12.2M
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 800,344
- Days to cover
- 3.59
- Change vs previous report
- -7.4%
FINRA short interest, settlement date Sep 15, 2026.